Loading ETF profile…
The Horizon Kinetics Medical ETF (the “Fund”) seeks long-term growth of capital. The Fund is an actively-managed exchange-traded fund (“ETF”) that will invest primarily in patented first line pharmaceuticals and biologics as these products tend to have high profit margins and significant barriers to entry. The Fund employs a long-term perspective, seeking to capture returns of both intrinsic valuation realization and scientific discovery.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| LLY | Eli Lilly & Co | 18.72% | $3.61M |
| ABBV | AbbVie Inc | 8.85% | $1.71M |
| — | US BANK MMDA - USBGFS 7 06/01/2031 | 7.18% | $1.38M |
| NVS | Novartis AG | 6.85% | $1.32M |
| JNJ | Johnson & Johnson | 5.63% | $1.09M |
| ALKS | Alkermes PLC | 5.48% | $1.06M |
| AZN | AstraZeneca PLC | 4.96% | $957.61K |
| IONS | Ionis Pharmaceuticals Inc | 4.56% | $879.84K |
| BMY | Bristol-Myers Squibb Co | 4.45% | $857.55K |
| MRK | Merck & Co Inc | 3.94% | $759.72K |
| AMGN | Amgen Inc | 3.85% | $743.45K |
| ALNY | Alnylam Pharmaceuticals Inc | 3.30% | $636.35K |
| BIIB | Biogen Inc | 3.06% | $590.53K |
| PFE | Pfizer Inc | 2.86% | $551.93K |
| CRSP | CRISPR Therapeutics AG | 2.70% | $520.00K |
| GSK | GSK PLC | 2.70% | $519.97K |
| REGN | Regeneron Pharmaceuticals Inc | 2.06% | $398.04K |
| BEAM | Beam Therapeutics Inc | 1.52% | $293.16K |
| GALT | Galectin Therapeutics Inc | 1.21% | $233.43K |
| NTLA | Intellia Therapeutics Inc | 1.08% | $209.02K |
| SDZNY | Sandoz Group AG | 0.79% | $152.95K |
| REPL | Replimune Group Inc | 0.73% | $140.94K |
| VNDA | Vanda Pharmaceuticals Inc | 0.72% | $139.06K |
| HLN | Haleon PLC | 0.60% | $114.84K |
| LTRN | Lantern Pharma Inc | 0.53% | $102.42K |